A Phase 2 interventional study of Trastuzumab deruxtecan in HER2-mutant Non-Small Cell Lung Cancer, sponsored by AstraZeneca. Active, not recruiting at 28 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung — 5 open to participants now, 9 under way, 2 of them phase 3. trastuzumab deruxtecan · Carcinoma, Non-Small-Cell Lung.
Among the 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung, this one is the 9th largest by enrollment, is the only one that started in 2022, is one of 7 in phase 2, and was the 7th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →5 of the 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Daiichi Sankyo · Sites in United States, Argentina, Belgium and 21 more countries
Ages 18+
AstraZeneca · Sites in United States, Australia, Belgium and 16 more countries
Ages 18+
Yonsei University · Sites in Korea, Republic of
Ages 20+
Centre Leon Berard · Sites in France
By country, each count listing its studies:
trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab deruxtecan is the treatment under test here. Read study by study →
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 2
First in 2017; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 167 across the 12 interventional studies. Of the 2 that completed or were terminated, 2 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 6 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca: 25 open now, 78 under way, 28 of them phase 3. Of 123 finished, 45 (37%) have results posted.
Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 92nd largest by enrollment of the 137 interventional ones that give a count, is one of 14 that started in 2022, is one of 38 in phase 2, reaches primary completion later than 21 of the 77 other live ones, and was the 156th registered.
AstraZeneca’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
3 of the studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06250777Yonsei UniversityEfficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases | 2026-12 |
| NCT07012031National Cancer Institute (NCI)Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation | 2027-06-14 |
| NCT04686305AstraZenecaPhase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among AstraZeneca’s 209 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of T-DXd in participants with HER2 mutant metastatic non-squamous NSCLC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive T-DXd as an IV infusion Q3W, on Day 1 of each 3-week cycle.
Drug: Trastuzumab deruxtecan
administered as an IV infusion
Also known as: T-DXd, DS-8201a
ICR-assessed ORR (Objective Response Rate)
Confirmed ORR, defined as the percentage of participants with confirmed complete response or partial response, as assessed by independent central review(ICR) based on RECIST 1.1.
Time frame: Tumour assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of enrolment and then every 9 weeks thereafter. Assessed up to 28 months. (from date of enrolment to final analysis data cut-off)
Investigator-assessed ORR (Objective Response Rate)
Confirmed ORR is defined as the percentage of participants who have a confirmed CR or confirmed PR, as determined by the investigator at local site per RECIST 1.1
Time frame: Tumour assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of enrolment and then every 9 weeks thereafter. Assessed up to 28 months. (from date of enrolment to final analysis data cut-off)
ICR-assessed DoR (Duration of Response)
DoR is time from the initial confirmed response (CR or PR) until documented tumour progression or death from any cause.
Time frame: Tumour assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of enrolment and then every 9 weeks thereafter. Assessed up to 28 months.
Investigator-assessed DoR (Duration of Response)
DoR is time from the initial confirmed response (CR or PR) until documented tumour progression or death from any cause.
Time frame: Tumour assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of enrolment and then every 9 weeks thereafter. Assessed up to 28 months.
ICR-assessed and Investigator-assessed DCR (Disease Control Rate)
DCR is the percentage of participants who achieved confirmed CR, PR, or SD during study intervention.
Time frame: Tumour assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of enrolment and then every 9 weeks thereafter. Assessed up to 28 months.
ICR-assessed and Investigator-assessed PFS (Progression-free Survival)
PFS is the time from date of enrolment until first objective radiographic tumour progression or death from any cause.
Time frame: Tumour assessments every 6 weeks after enrolment for the first 48 weeks and then every 9 weeks thereafter until date of RECIST 1.1 defined radiological progressive disease or death. Assessed up to 28 months.
OS (Overall Survival)
OS is the time from date of enrolment until death from any cause.
Time frame: From date of enrolment until death due to any cause. Assessed up to 28 months.
ICR-assessed CNS-PFS (Central Nervous System Progression-free Survival)
CNS-PFS is the time from date of enrolment until CNS tumour progression per RECIST 1.1 as assessed by ICR or death due to any cause in the absence of CNS progression.
Time frame: Tumour assessments every 6 weeks after enrolment for the first 48 weeks and then every 9 weeks thereafter until date of RECIST 1.1 defined CNS tumour progressive disease or death in the absence of CNS progression. Assessed up to 28 months.
Serum Concentrations of T-DXd
Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for T-DXd.
Time frame: 24 weeks from day 1 of cycle 1 to cycle 8
Serum Concentrations of Total Anti-HER2 Antibody
Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for total anti-HER2 antibody.
Time frame: 24 weeks from day 1 of cycle 1 to cycle 8
Serum Concentrations of DXd
Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for DXd.
Time frame: 24 weeks from day 1 of cycle 1 to cycle 8
| Milestone | T-DXd Arm |
|---|---|
| Started | 72 |
| Completed | 29 |
| Not completed | 43 |
| Withdrew: Death | 41 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal by subject | 1 |
Confirmed ORR is defined as the percentage of participants who have a confirmed CR or confirmed PR, as determined by the investigator at local site per RECIST 1.1
| Percentage of participants | T-DXd Arm |
|---|---|
| Investigator-assessed ORR (Objective Response Rate) | 59.7 (47.5 to 71.1) |
DoR is time from the initial confirmed response (CR or PR) until documented tumour progression or death from any cause.
| Months | T-DXd Arm |
|---|---|
| ICR-assessed DoR (Duration of Response) | 11.6 (5.8 to NA) |
DoR is time from the initial confirmed response (CR or PR) until documented tumour progression or death from any cause.
| Months | T-DXd Arm |
|---|---|
| Investigator-assessed DoR (Duration of Response) | 9.4 (7.2 to 13.5) |
DCR is the percentage of participants who achieved confirmed CR, PR, or SD during study intervention.
| Percentage of participants | T-DXd Arm |
|---|---|
| ICR-assessed | 91.7 (82.7 to 96.9) |
| Investigator-assessed | 93.1 (84.5 to 97.7) |
PFS is the time from date of enrolment until first objective radiographic tumour progression or death from any cause.
| Months | T-DXd Arm |
|---|---|
| ICR-assessed | 9.9 (7.1 to 16.5) |
| Investigator-assessed | 9.7 (8.1 to 13.4) |
OS is the time from date of enrolment until death from any cause.
| Months | T-DXd Arm |
|---|---|
| OS (Overall Survival) | 21.0 (17.5 to NA) |
CNS-PFS is the time from date of enrolment until CNS tumour progression per RECIST 1.1 as assessed by ICR or death due to any cause in the absence of CNS progression.
| Months | T-DXd Arm |
|---|---|
| ICR-assessed CNS-PFS (Central Nervous System Progression-free Survival) | 15.5 (9.9 to NA) |
Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for T-DXd.
| μg/mL | T-DXd Arm |
|---|---|
| Cycle 1 Pre-dose | NA ± NA |
| Cycle 1 End of infusion | 120.5 ± 18.33 |
| Cycle 1 5 hour post-dose | 106.1 ± 77.96 |
| Cycle 2 Pre-dose | 3.072 ± 121.6 |
| Cycle 2 End of infusion | 117.4 ± 18.79 |
| Cycle 3 Pre-dose | 5.262 ± 111.2 |
| Cycle 3 End of infusion | 120.9 ± 17.04 |
| Cycle 4 Pre-dose | 8.014 ± 60.69 |
| Cycle 4 End of infusion | 118.4 ± 18.44 |
| Cycle 6 Pre-dose | 9.024 ± 67.20 |
| Cycle 8 Pre-dose | 10.39 ± 65.12 |
Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for total anti-HER2 antibody.
| ug/mL | T-DXd Arm |
|---|---|
| Cycle 1 Pre-dose | NA ± NA |
| Cycle 1 End of infusion | 127.5 ± 21.93 |
| Cycle 1 5 hour post-dose | 118.0 ± 18.85 |
| Cycle 2 Pre-dose | 2.866 ± 148.7 |
| Cycle 2 End of infusion | 120.1 ± 39.66 |
| Cycle 3 Pre-dose | 4.582 ± 126.4 |
| Cycle 3 End of infusion | 125.9 ± 16.87 |
| Cycle 4 Pre-dose | 6.974 ± 84.38 |
| Cycle 4 End of infusion | 121.3 ± 16.80 |
| Cycle 6 Pre-dose | 8.049 ± 94.39 |
| Cycle 8 Pre-dose | 9.579 ± 83.64 |
Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for DXd.
| ng/mL | T-DXd Arm |
|---|---|
| Cycle 1 Pre-dose | NA ± NA |
| Cycle 1 End of infusion | 5.384 ± 47.55 |
| Cycle 1 5 hour post-dose | 12.90 ± 69.38 |
| Cycle 2 Pre-dose | 0.1751 ± 119.4 |
| Cycle 2 End of infusion | 2.657 ± 70.96 |
| Cycle 3 Pre-dose | 0.2423 ± 110.6 |
| Cycle 3 End of infusion | 2.310 ± 50.12 |
| Cycle 4 Pre-dose | 0.3226 ± 53.71 |
| Cycle 4 End of infusion | 2.139 ± 51.35 |
| Cycle 6 Pre-dose | 0.3286 ± 58.35 |
| Cycle 8 Pre-dose | 0.3749 ± 54.09 |
Confirmed ORR, defined as the percentage of participants with confirmed complete response or partial response, as assessed by independent central review(ICR) based on RECIST 1.1.
| Percentage of participants | T-DXd Arm |
|---|---|
| ICR-assessed ORR (Objective Response Rate) | 56.9 (44.7 to 68.6) |
Collected over From date of informed consent throughout the treatment period and the safety follow-up period (until 40 (+7) days after the last dose of study treatment).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| T-DXd | 41/72 (56.9%) | 41/72 (56.9%) | 72/72 (100%) |
| Event | T-DXd |
|---|---|
| Platelet count decreasedInvestigations | 6/72 |
| Covid-19Infections and infestations | 5/72 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 5/72 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 5/72 |
| VomitingGastrointestinal disorders | 4/72 |
| Covid-19 pneumoniaInfections and infestations | 4/72 |
| DeathGeneral disorders | 2/72 |
| AnaemiaBlood and lymphatic system disorders | 2/72 |
| Herpes zosterInfections and infestations | 2/72 |
| PneumoniaInfections and infestations | 2/72 |
| Event | T-DXd |
|---|---|
| Platelet count decreasedInvestigations | 48/72 |
| White blood cell count decreasedInvestigations | 48/72 |
| Neutrophil count decreasedInvestigations | 47/72 |
| AnaemiaBlood and lymphatic system disorders | 46/72 |
| NauseaGastrointestinal disorders | 43/72 |
| Aspartate aminotransferase increasedInvestigations | 43/72 |
| Alanine aminotransferase increasedInvestigations | 36/72 |
| Decreased appetiteMetabolism and nutrition disorders | 31/72 |
| VomitingGastrointestinal disorders | 26/72 |
| Covid-19Infections and infestations | 26/72 |
| Age, Continuous(Years) | T-DXd Arm |
|---|---|
| Median | 57.0 (34 to 76) |
| Age, Continuous(Years) | T-DXd Arm |
|---|---|
| Mean | 57.4 ± 9.74 |
| Sex: Female, Male(Participants) | T-DXd Arm |
|---|---|
| Female | 41 |
| Male | 31 |
| Ethnicity (NIH/OMB)(Participants) | T-DXd Arm |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 72 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | T-DXd Arm |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 72 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jul 2022 to primary completion in Nov 2024, 27 months.
Results were first posted in Dec 2024, 1 month after primary completion.
Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 27 months is below that.
Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab deruxtecan
Carcinoma, Non-Small-Cell Lung →